Management of haemophilia A with inhibitors: A regional cross‐talk-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Management of haemophilia A with inhibitors: A regional cross‐talk

Published:2022-07-22 Issue:6 Volume:28 Page:950-961
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Peyvandi Flora¹²^ORCID,Kavakli Kaan³,El‐Beshlawy Amal⁴,Rangarajan Savita⁵⁶

Affiliation:

1. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy

2. Department of Pathophysiology and Transplantation Università degli Studi di Milanoo Milan Italy

3. Department of Pediatric Hematology Ege University Children's Hospital Izmir Turkey

4. Department of Pediatric Hematology, Faculty of Medicine Cairo University Cairo Egypt

5. Department of Haematology University Hospital Southampton NHS Foundation Trust Southampton UK

6. Clinical Trials and Research Unit KJ Somaiya Super Specialty Hospital and Research Centre Mumbai India

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14638

Reference107 articles.

1. Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel

2. The past and future of haemophilia: diagnosis, treatments, and its complications

3. Modern haemophilia care

4.

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence

5. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: A critical systematic review

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Large deletions and small insertions and deletions in the factor VIII gene predict unfavorable immune tolerance induction outcome in people with severe hemophilia A and high-responding inhibitors;Thrombosis Research;2024-10

2. The self-reactive FVIII T cell repertoire in healthy individuals relies on a short set of epitopes and public clonotypes;Frontiers in Immunology;2024-03-06

3. Budget impact and cost-utility analysis of prophylactic emicizumab versus on-demand bypassing agents for adolescent severe haemophilia A patients with inhibitors in India;Heliyon;2024-03

4. Generation and pathogenicity of autoantibodies associated to thrombosis and hemostasis;Exploration of Immunology;2024-02-05

5. Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes;Research and Practice in Thrombosis and Haemostasis;2023-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3